Chongqing Lummy Pharmaceutical Co., Ltd.

Chongqing Lummy Pharmaceutical Co., Ltd. faced a notable stock decline, contrasting with broader market trends. The company has struggled financially, reporting losses for six consecutive quarters and a negative net worth. Its long-term performance reflects significant declines, indicating ongoing challenges in the pharmaceuticals and biotechnology sector.

Chongqing Lummy Pharmaceutical Co., Ltd. saw a notable rise in stock performance on June 30, 2026, achieving an intraday high of CNY 5.55. The company has outperformed the China Shanghai Composite index recently, although it faces challenges such as low return on capital and a history of negative net profit.

Chongqing Lummy Pharmaceutical Co., Ltd. has seen a notable decline in its stock performance, contrasting with the broader market. The company has faced challenges, including negative net profit and declining net sales over the past five years, despite a strong yearly performance. Its market capitalization is CNY 5,141 million.

Chongqing Lummy Pharmaceutical Co., Ltd. has seen a notable rise in its stock performance, achieving an intraday high and outperforming the China Shanghai Composite index. Despite recent gains and a strong annual return, the company faces challenges such as low returns on capital and declining net sales.